(Q40384835)

20 September 2017

title

Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles (English)

1 reference

20 September 2017

3

Martin Fussenegger

1 reference

20 September 2017

Barbara Mitta

1

1 reference

20 September 2017

Markus Rimann

series ordinal

2

1 reference

20 September 2017

publication date

15 August 2005

1 reference

20 September 2017

published in

Metabolic Engineering

1 reference

20 September 2017

volume

7

1 reference

20 September 2017

issue

5-6

1 reference

20 September 2017

page(s)

426-436

1 reference

Gene therapy scores against cancer

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Lentiviral vectors for treating and modeling human CNS disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Virus entry, assembly, budding, and membrane rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Prolonged liver-specific transgene expression by a non-primate lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Complete amino acid sequence of the nucleic acid‐binding protein of bovine leukemia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Transfer of genes to humans: early lessons and obstacles to success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Transduction of a gene expression cassette using advanced generation lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Serum-free large-scale transient transfection of CHO cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Dual-regulated expression of C/EBP-alpha and BMP-2 enables differential differentiation of C2C12 cells into adipocytes and osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Streptogramin- and tetracycline-responsive dual regulated expression of p27(Kip1) sense and antisense enables positive and negative growth control of Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Kinetic analyses of stability of simple and complex retroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55(gag) associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Gene transduction efficiency in cells of different species by HIV and EIAV vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Transfection of adherent and suspended cells by calcium phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Optimized conditions for the production of recombinant amphotropic retroviral vector preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

A stable system for the high-titer production of multiply attenuated lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Kinetics of retrovirus production and decay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Scale-up of virus-like particles production: effects of sparging, agitation and bioreactor scale on cell growth, infection kinetics and productivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

State-of-the-art of the production of retroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

In vivo transduction of HIV-1-derived lentiviral particles engineered for macrolide-adjustable transgene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Antibody-directed targeting of retroviral vectors via cell surface antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Nonviral vectors in the new millennium: delivery barriers in gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Amino-terminal sequence of bovine leukemia virus major internal protein: homology with mammalian type C virus p30 structural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Development of multigene and regulated lentivirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Gene therapy: trials and tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Cre-lox-regulated conditional RNA interference from transgenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Human gene therapy — of tortises and hares

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Development of stable cell lines for production or regulated expression using matrix attachment regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Effective polyethylenimine-mediated gene transfer into human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

inferred from DOI database lookup

7 January 2021

based on heuristic

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2005.06.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMBEN.2005.06.006

1 reference

20 September 2017

1 reference